Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

821. Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection

Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection Lanza L A, Visbal A I, DeValeria P A, Zinsmeister A R, Diehl N N, Trastek V F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of low-dose oral amiodarone (LDOA) as prophylactic treatment for atrial fibrillation (AF) after pulmonary resection. LDOA comprised 200 mg by mouth every 8 hours. Treatment was started after recovery from general anaesthesia and was discontinued at dismissal. Type of intervention Secondary prevention. Economic study type

2003 NHS Economic Evaluation Database.

822. Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation

Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation De Paola A A, Figueiredo E, Sesso R, Veloso H H, Nascimento L O Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of chemical versus electrical cardioversion as an initial treatment to convert atrial fibrillation (AF) to sinus rhythm in patients with persistent AF of less than 6 months. The authors not only compared the initial strategies, but they also evaluated whether a strategy that started with either method followed

2003 NHS Economic Evaluation Database.

823. Atrial fibrillation ablation leads to long-term improvement of quality of life and reduced utilization of healthcare resources

Atrial fibrillation ablation leads to long-term improvement of quality of life and reduced utilization of healthcare resources Atrial fibrillation ablation leads to long-term improvement of quality of life and reduced utilization of healthcare resources Atrial fibrillation ablation leads to long-term improvement of quality of life and reduced utilization of healthcare resources Goldberg A, Menen M, Mickelsen S, MacIndoe C, Binder M, Nawman R, West G, Kusumoto F M Record Status (...) . Study population The study population comprised patients referred for radiofrequency catheter ablation for drug refractory atrial fibrillation. Setting The setting was secondary care. The economic study was carried out in Albuquerque, USA. Dates to which data relate The effectiveness data were collected for patients referred to the medical centre between June 1996 and June 1997. The cost information was collected for the same time period. The price year was 2001. Source of effectiveness data

2003 NHS Economic Evaluation Database.

824. Atrial fibrillation: strategies to control, combat, and cure. (Abstract)

Atrial fibrillation: strategies to control, combat, and cure. Atrial fibrillation is the commonest clinical arrhythmia, is increasing in incidence and prevalence, and is associated with substantial morbidity and mortality. The arrhythmia may be paroxysmal (self-limiting), persistent (amenable to cardioversion), or permanent. Especially in its paroxysmal form, atrial fibrillation may be initiated by rapidly firing foci, generally located in the proximal pulmonary veins. Sustained atrial (...) fibrillation is maintained by an atrial tissue substrate capable of accommodating many meandering wavelets. With continuing arrhythmia, the electrophysiological properties of the atria change and further facilitate continuing fibrillation. Treatment is aimed at prevention of thromboembolic complications, restoration and maintenance of sinus rhythm, and control of ventricular rate during atrial fibrillation. With greater understanding of the arrhythmia mechanisms, it is becoming possible to offer targeted

2002 Lancet

825. Electrical cardioversion for atrial fibrillation and flutter. (Abstract)

Electrical cardioversion for atrial fibrillation and flutter. Atrial fibrillation increases the risk of stroke, increases the risk of cognitive impairment, and adversely affects cardiovascular haemodynamics. Electrical cardioversion for atrial fibrillation has been in use since the 1960s; the rationale is that restoration of sinus rhythm improves cardiovascular haemodynamics, reduces the risk of stroke, and obviates the need for long-term anticoagulation.To assess the effects of electrical (...) cardioversion of atrial fibrillation or atrial flutter on the annual risk of thromboembolic events, strokes and mortality (primary outcomes measures), the rate of cognitive decline, quality of life, the use of anticoagulants and the risk of re-hospitalisation (secondary outcome measures) in adults (>18 years) with acute, paroxysmal or sustained atrial fibrillation or atrial flutter, of any duration and any aetiology.One reviewer searched the Cochrane Controlled Clinical Trials Register (2000 Issue 4

2002 Cochrane

826. A comparison of rate control and rhythm control in patients with atrial fibrillation. (Abstract)

A comparison of rate control and rhythm control in patients with atrial fibrillation. There are two approaches to the treatment of atrial fibrillation: one is cardioversion and treatment with antiarrhythmic drugs to maintain sinus rhythm, and the other is the use of rate-controlling drugs, allowing atrial fibrillation to persist. In both approaches, the use of anticoagulant drugs is recommended.We conducted a randomized, multicenter comparison of these two treatment strategies in patients (...) with atrial fibrillation and a high risk of stroke or death. The primary end point was overall mortality.A total of 4060 patients (mean [+/-SD] age, 69.7+/-9.0 years) were enrolled in the study; 70.8 percent had a history of hypertension, and 38.2 percent had coronary artery disease. Of the 3311 patients with echocardiograms, the left atrium was enlarged in 64.7 percent and left ventricular function was depressed in 26.0 percent. There were 356 deaths among the patients assigned to rhythm-control therapy

2002 NEJM Controlled trial quality: uncertain

827. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. Full Text available with Trip Pro

A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. Maintenance of sinus rhythm is the main therapeutic goal in patients with atrial fibrillation. However, recurrences of atrial fibrillation and side effects of antiarrhythmic drugs offset the benefits of sinus rhythm. We hypothesized that ventricular rate control is not inferior to the maintenance of sinus rhythm for the treatment of atrial fibrillation.We randomly assigned 522 patients who (...) had persistent atrial fibrillation after a previous electrical cardioversion to receive treatment aimed at rate control or rhythm control. Patients in the rate-control group received oral anticoagulant drugs and rate-slowing medication. Patients in the rhythm-control group underwent serial cardioversions and received antiarrhythmic drugs and oral anticoagulant drugs. The end point was a composite of death from cardiovascular causes, heart failure, thromboembolic complications, bleeding

2002 NEJM Controlled trial quality: uncertain

828. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. (Abstract)

Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. External cardioversion is a readily available treatment for persistent atrial fibrillation. Although anatomical and electrophysiological considerations suggest that an anterior-posterior electrode position should create a more homogeneous shock-field gradient throughout the atria than an anterior-lateral position, both electrode positions are equally recommended (...) for external cardioversion in current guidelines. We undertook a randomised trial comparing the two positions with the endpoint of successful cardioversion.108 consecutive patients (mean age 60 years [SD 16]) with persistent atrial fibrillation (median duration 5 months, range 0.1-120) underwent elective external cardioversion by a standardised step-up protocol with increasing shock strengths (50-360 J). Electrode positions were randomly assigned as anterior-lateral or anterior-posterior. If sinus rhythm

2002 Lancet Controlled trial quality: uncertain

829. An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery

An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery Reddy P, Dunn A B, White C M, Tsikouris J P, Giri S, Kluger J Record Status This is a critical abstract of an economic evaluation that meets (...) reported. A sample size of 100 patients per group was needed to assure 0.80 power in the detection of a 50% difference in postoperative atrial fibrillation rate, with an anticipated 33% rate in the placebo group. A total of 220 patients (168 men, 52 women) were included in the study, with an approximate 10% drop-out rate anticipated after selection. Of these, 120 (74 men) were assigned to the amiodarone group (receiving amiodarone plus beta-blockers) and the remaining 100 (94 men) to the placebo group

2002 NHS Economic Evaluation Database.

830. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials

Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials Hilleman D E, Spinler S A Authors' objectives To evaluate the efficacy and safety of intravenous amiodarone for conversion (...) of recent-onset atrial fibrillation (AF). Searching MEDLINE was searched from January 1975 to March 2001 for studies published in the English language. The search terms were 'atrial fibrillation', 'amiodarone' and 'cardioversion'. Pertinent review articles and the reference lists in the identified studies were examined for additional studies. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were eligible. Specific interventions included

2002 DARE.

831. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation

Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation Nichol G, McAlister F, Pham B (...) , Laupacis A, Shea B, Green M, Tang A, Wells G Authors' objectives To assess the effectiveness of anti-arrhythmic drugs at promoting sinus rhythm in patients with atrial fibrillation by conducting a meta-analysis of randomised controlled trials (RCTs). Searching MEDLINE was searched for trials for which results were available by August 2001; the search terms were reported. The bibliographies of relevant articles were examined. Only articles published in the English language were sought. Unpublished

2002 DARE.

832. Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting

Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary (...) patients who received amiodarone 1-week preoperatively and 0.93 in those who received the treatment postoperatively, (p=0.56). Synthesis of costs and benefits Irrelevant since a cost-consequences analysis was carried out. Authors' conclusions The clinical pathway using amiodarone for the prevention of atrial fibrillation (AF) in patients who had undergone coronary artery bypass grafting (CABG) was effective in reducing the incidence of postoperative AF. However, there was no corresponding reduction

2002 NHS Economic Evaluation Database.

833. A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin

A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin Kim M H, Morady F, Conlon B, Kronick S, Lowell M (...) , Bruckman D, Armstrong W F, Eagle K A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two approaches for the management of low-risk patients with newly diagnosed or new-onset atrial fibrillation (AF) were examined. The approaches were

2002 NHS Economic Evaluation Database.

834. Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis

Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis Desbiens N A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention examined in the study was anticoagulation treatment with warfarin in patients with nonrheumatic atrial fibrillation (AF). Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised patients aged 65 to 100 years with nonrheumatic AF. Setting

2002 NHS Economic Evaluation Database.

835. Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial

Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Lumer G B, Roy D, Talajic M, Couturier A, Lambert J, Frasure-Smith N, Thibault B, Dubuc M, Gagne P, Nattel S Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Low-dose amiodarone was compared with other first-line therapy (sotalol or propafenone) for the treatment of atrial fibrillation (AF). Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population

2002 NHS Economic Evaluation Database.

836. Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation

Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation Mahoney E M, Thompson T D, Veledar E, Williams J, Weintraub W S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of prophylactic intravenous (IV) amiodarone therapy for the prevention of atrial fibrillation (AF) in patients undergoing cardiac surgery. Type of intervention Secondary prevention. Economic study type

2002 NHS Economic Evaluation Database.

837. The maze procedure in treating atrial fibrillation

The maze procedure in treating atrial fibrillation The maze procedure in treating atrial fibrillation We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services The maze procedure in treating atrial fibrillation Share: Reading time approx. 10 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings (...) by SBU Alert Version: 1 Technology and target group Atrial fibrillation is a common disorder that impairs cardiac function and increases the risk for thrombosis. Primarily, medication is used to treat the disorder, but surgery becomes an option if medication or other non-pharmacological treatment alternatives are insufficient. The Maze procedure is an open surgical intervention that can be used to treat particularly severe cases of atrial fibrillation. Eleven incisions are strategically placed

2002 Swedish Council on Technology Assessement

838. Atrial fibrillation after cardiac surgery. (Abstract)

Atrial fibrillation after cardiac surgery. To review the epidemiology, mechanisms, complications, predictors, prevention, and treatment of atrial fibrillation following cardiac surgery.MEDLINE search of English-language reports published between 1966 and 2000 and a search of references of relevant papers.Clinical and basic research studies on atrial fibrillation after cardiac surgery.Relevant clinical information was extracted from selected articles.Atrial fibrillation occurs in 10% to 65 (...) % of patients after cardiac surgery, usually on the second or third postoperative day. Postoperative atrial fibrillation is associated with increased morbidity and mortality and longer, more expensive hospital stays. Prophylactic use of beta-adrenergic blockers reduces the incidence of postoperative atrial fibrillation and should be administered before and after cardiac surgery to all patients without contraindication. Prophylactic amiodarone and atrial overdrive pacing should be considered in patients

2001 Annals of Internal Medicine

839. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Full Text available with Trip Pro

Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. To determine and compare physicians' and patients' thresholds for how much reduction in risk of stroke is necessary and how much risk of excess bleeding is acceptable with antithrombotic treatment in people with atrial fibrillation.Prospective observational study.Tertiary and peripheral referral centres in Nova Scotia, Canada.63 physicians who were treating (...) patients with atrial fibrillation and 61 patients at high risk for atrial fibrillation.Participants underwent a face to face interview with a probability trade-off tool. Thresholds were determined for the minimum reduction in risk of stroke necessary and the maximum increase in risk of excess bleeding acceptable for treatment with aspirin and warfarin in people with atrial fibrillation.The minimum number of strokes that needed to be prevented in 100 patients over two years for warfarin to be justified

2001 BMJ

840. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. (Abstract)

Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Atrial fibrillation (AF) carries a high risk of stroke and other thromboembolic events. Appropriate use of drugs to prevent thromboembolism in patients with AF involves comparing the patient's risk of stroke to the risk of hemorrhage from medication use.To quantify risk of stroke, major hemorrhage and death from using medications that have been rigorously evaluated for prevention of thromboembolism

2001 Cochrane